CERO - CERo Therapeutics Holdings, Inc. Common Stock

Day	1m	10m	60m	PreMarket	Market	AfterHours	Gap
2.85 -0.25 (-8.78%)	0.0 (0.0%)	0.0 (0.0%)	0.0 (0.0%)	0.0 (0.0%)	-0.27 (-9.41%)	0.0 (0.0%)	0.0 (0.0%)

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.

Category: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

Market Period: Closed

Earnings & Ratios

Basic EPS:: -61.71
Diluted EPS:: -61.71
Basic P/E:: -0.0421
Diluted P/E:: -0.0421
RSI(14) 1m:: 40.0
VWAP:: 2.6
RVol:: 1.7872

Events

Period	Kind	Movement	Occurred At
1m	Price decrease 1m	2.59 -0.05 (-1.8%)	Oct 15 15:06
1m	Price increase 1m	2.64 +0.03 (+1.05%)	Oct 15 11:30
60m	Price decrease 60m	2.64 -0.16 (-5.71%)	Oct 15 10:59
1m	Price decrease 1m	2.73 -0.03 (-1.07%)	Oct 15 10:36
1m	Price increase 1m	2.8 +0.04 (+1.45%)	Oct 15 10:10